Oculis Holding AG (NASDAQ:OCS) Short Interest Up 69.3% in June

Oculis Holding AG (NASDAQ:OCS) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 1,102,658 shares, an increase of 69.3% from the May 31st total of 651,247 shares. Based on an average trading volume of 1,672,824 shares, the short-interest ratio is currently 0.7 days. Currently, 1.9% of the company’s shares are sold short.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Bank of America Corp DE grew its holdings in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC bought a new position in Oculis in the 4th quarter valued at about $80,000. Geode Capital Management LLC lifted its position in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Finally, Koshinski Asset Management Inc. acquired a new position in Oculis during the 1st quarter valued at about $238,000. 22.30% of the stock is owned by institutional investors.

Oculis Stock Up 4.6%

OCS stock traded up $0.62 during trading on Thursday, reaching $14.15. 313,505 shares of the stock were exchanged, compared to its average volume of 514,675. The firm’s 50 day moving average is $21.03 and its 200 day moving average is $23.97. The firm has a market cap of $820.36 million, a P/E ratio of -6.62 and a beta of 0.45. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. Oculis has a twelve month low of $10.52 and a twelve month high of $34.47.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, research analysts forecast that Oculis will post -2.27 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Robert W. Baird cut their target price on Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a research report on Monday, June 1st. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Needham & Company LLC dropped their price target on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Guggenheim cut their price target on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Oculis in a research report on Thursday, June 11th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Oculis currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.